<a id="bm-comp-898fa1c1-7491-4797-87cf-04789485d86d" name="bm-comp-898fa1c1-7491-4797-87cf-04789485d86d" class="BMCustomAnchor"></a><table><tr><td bm-component-id="898fa1c1-7491-4797-87cf-04789485d86d" style="vertical-align: top; width:100.000000%;"><ul><li>Orviglance FDA submission during the summer</li><li>Good cost control</li><li><a data-bm-trackable="false" href="https://ascelia-pharma.events.inderes.com/q1-report-2025" target="_blank">Conf call</a> at 10:00 CEST</li></ul></td></tr></table><a id="bm-comp-581cb381-47f5-476b-8b6d-ddb371570c34" name="bm-comp-581cb381-47f5-476b-8b6d-ddb371570c34" class="BMCustomAnchor"></a><table><tr><td bm-component-id="581cb381-47f5-476b-8b6d-ddb371570c34" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Recent relevant events</h3><p>In mid'March '25, Ascelia communicated a positive outcome of the pre-NDA meeting with the FDA. In mid'April, Ascelia finished the warrants TO 1 capital raise, raising gross proceeds of SEK 43m. On 7 May, Ascelia held its AGM in Malmö, adopting all resolutions on the agenda. All board members including the chairman of the board were re-elected. Earlier this week, Ascelia's CEO Magnus Corfitzen held a presentation at the ABG Investor days and Ascelia clinical collaborators presented SPARKLE data at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting.</p><h3 class="bm-h3">Financials</h3><p>Operating cash flow was SEK -16.9m (SEK -18.8m in Q4'24). Cash and cash equivalents came in at SEK 57.3m (SEK 75.3m in Q4'24). The proceeds from the exercise of the warrants TO 1 (gross SEK ~43m) will be booked in Q2'25. Approximately half (SEK 20m) of the warrants TO 1 net proceeds are used to repay the remaining 2024 Fenja Capital loan. Following this, Fenja holds convertibles worth SEK 7.5m, which can be converted up to and including 31 Dec 2025 at a conversion price of SEK 3.38/share.</p><h3 class="bm-h3">Upcoming milestones</h3><p>The New Drug Application (NDA) submission to the US FDA is planned in mid'25 (mid'May-mid'Aug). Ascelia will host a <a data-bm-trackable="false" href="https://ascelia-pharma.events.inderes.com/q1-report-2025" target="_blank">conference call</a> today at 10:00 CEST.</p></td></tr></table>